{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T21:27:04Z","timestamp":1768771624707,"version":"3.49.0"},"reference-count":14,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100012351","name":"Mitsubishi Tanabe Pharma Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012351","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.clinthera.2020.06.016","type":"journal-article","created":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T22:16:01Z","timestamp":1597356961000},"page":"1467-1482.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Open-label, Single-dose Studies of the Pharmacokinetics of Edaravone in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects with Normal Hepatic Functioning"],"prefix":"10.1016","volume":"42","author":[{"given":"Yoshinobu","family":"Nakamaru","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masae","family":"Kakubari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaori","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Akimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8001-3570","authenticated-orcid":false,"given":"Vesna","family":"Todorovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Greis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuoki","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"suppl 1","key":"10.1016\/j.clinthera.2020.06.016_bib1","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1080\/21678421.2017.1353100","article-title":"Pharmacokinetic profile of edaravone: a comparison between Japanese and Caucasian populations","volume":"18","author":"Nakamaru","year":"2017","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"10.1016\/j.clinthera.2020.06.016_bib2","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/j.clinthera.2018.08.009","article-title":"Bioavailability of edaravone sublingual tablet versus intravenous infusion in healthy male volunteers","volume":"40","author":"Wang","year":"2018","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2020.06.016_bib3","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1007\/s40262-018-0655-4","article-title":"Two decades-long journey from riluzole to edaravone: revisiting the clinical pharmacokinetics of the only two amyotrophic lateral sclerosis therapeutics","volume":"57","author":"Dash","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2020.06.016_bib4","series-title":"Radicava (Edaravone) Injection. Clinical Pharmacology and Biopharmaceutics Review(s)","author":"Center for Drug Evaluation and Research","year":"2016"},{"key":"10.1016\/j.clinthera.2020.06.016_bib5","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1872-034X.2010.00751.x","article-title":"Clinical evaluation of liver injury in patients with acute ischemic brain stroke treated with edaravone","volume":"41","author":"Hirano","year":"2011","journal-title":"Hepatol Res"},{"key":"10.1016\/j.clinthera.2020.06.016_bib6","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s10157-008-0108-8","article-title":"Determinants for the prognosis of acute renal disorders that developed during or after treatment with edaravone","volume":"13","author":"Hishida","year":"2009","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.clinthera.2020.06.016_bib7","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s10157-007-0495-2","article-title":"Clinical analysis of 207 patients who developed renal disorders during or after treatment with edaravone reported during post-marketing surveillance","volume":"11","author":"Hishida","year":"2007","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.clinthera.2020.06.016_bib9","series-title":"Guidance for Industry\u2014Pharmacokinetics in Patients with Impaired Hepatic Function\u2014Study Design, Data Analysis, and Impact on Dosing and Labeling","author":"US Food and Drug Administration","year":"2003"},{"key":"10.1016\/j.clinthera.2020.06.016_bib11","series-title":"Radicava (Edaravone) Injection","year":"2017"},{"key":"10.1016\/j.clinthera.2020.06.016_bib12","first-page":"403","article-title":"Japan association of chronic kidney disease initiatives","volume":"54","author":"Imai","year":"2011","journal-title":"JMAJ"},{"key":"10.1016\/j.clinthera.2020.06.016_bib13","article-title":"An open-label, single-dose study to evaluate the pharmacokinetic variables of edaravone in participants with mild, moderate, or no renal impairment.","author":"Nakamaru","year":"2020","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2020.06.016_bib15","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s00228-008-0553-z","article-title":"Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction","volume":"64","author":"Verbeeck","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2020.06.016_bib16","first-page":"17","article-title":"Relevance of liver failure for anti-infective agents: from pharmacokinetic alterations to dosage adjustments","volume":"2","author":"B\u00fcdingen","year":"2014","journal-title":"Ther Adv Infect Dis"},{"key":"10.1016\/j.clinthera.2020.06.016_bib17","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1124\/dmd.106.013912","article-title":"Human organic anion transporters 1 (hOAT1\/SLC22A6) and 3 (hOAT3\/SLC22A8) transport edaravone (MCI-186; 3-methyl-1-phenyl-2-pyrazolin-5-one) and its sulfate conjugate","volume":"35","author":"Mizuno","year":"2007","journal-title":"Drug Metab Dispos"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929182030326X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929182030326X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:53:20Z","timestamp":1758963200000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014929182030326X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":14,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S014929182030326X"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2020.06.016","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Open-label, Single-dose Studies of the Pharmacokinetics of Edaravone in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects with Normal Hepatic Functioning","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2020.06.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}